正在加载公司
IceCure Medical Ltd.
ICCM · Nasdaq · ·
US$1.60-3.3%9月29日 收盘
- 1M
- -29.8%
- 6M
- -82.3%
- 1Y
- -94.6%
- 5Y
- -99.4%
ICCM · Nasdaq · ·
US$1.60-3.3%9月29日 收盘
取自公司自己的 6-K 文件。
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company’s flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
公司自己的描述，取自公告末尾。
引述和公司简介来自 IceCure Medical Ltd. 于 2025年11月19日 随业绩提交的 6-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
暂无 IceCure Medical Ltd. 的业绩电话会文字记录。